Pembrolizumab Combo Shows Efficacy in Pediatric High-Risk Hodgkin Lymphoma - CancerNetwork
Pembrolizumab Combo Shows Efficacy in Pediatric High-Risk Hodgkin Lymphoma CancerNetwork
Hodgkin Lymphoma News
Delta Goodrem Inspiring Cancer Journey: Hodgkin Lymphoma, Recovery, and Eurovision Return - Oncodaily
Delta Goodrem Inspiring Cancer Journey: Hodgkin Lymphoma, Recovery, and Eurovision Return Oncodaily
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas - OncLive
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas OncLive
Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics - WCM Newsroom
Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics WCM Newsroom
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal - Nature
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal Nature
Soligenix axes lymphoma program after phase 3 setback, mulls M&A options - Fierce Biotech
Soligenix axes lymphoma program after phase 3 setback, mulls M&A options Fierce Biotech
Brown-Shuler to Undergo Treatment for Hodgkin Lymphoma - Clemson University Athletics
Brown-Shuler to Undergo Treatment for Hodgkin Lymphoma Clemson University Athletics
Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma - CancerNetwork
Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma CancerNetwork
Legend Biotech Establishes Clinical Proof-of-Concept for - GlobeNewswire
Legend Biotech Establishes Clinical Proof-of-Concept for GlobeNewswire
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma - Targeted Oncology
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma Targeted Oncology
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy - UT MD Anderson
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy UT MD Anderson
Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report - Nature
Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report Nature
FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma - OncLive
FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma OncLive
BrECADD Improves PFS Vs Nivolumab/AVD in Advanced-Stage Hodgkin Lymphoma - CancerNetwork
BrECADD Improves PFS Vs Nivolumab/AVD in Advanced-Stage Hodgkin Lymphoma CancerNetwork
Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors - Nature
Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors Nature
AZD3470 Displays Clinical Activity in Pretreated Classic Hodgkin Lymphoma - CancerNetwork
AZD3470 Displays Clinical Activity in Pretreated Classic Hodgkin Lymphoma CancerNetwork
Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study - Nature
Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study Nature
Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma - CancerNetwork
Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma CancerNetwork
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era - CancerNetwork
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era CancerNetwork
Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma - CancerNetwork
Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma CancerNetwork
Non-Hodgkin lymphoma survivor thankful for clinical trial - UT MD Anderson
Non-Hodgkin lymphoma survivor thankful for clinical trial UT MD Anderson
Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma - The ASCO Post
Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma The ASCO Post
Single-dose lymphoma CAR-T from Legend Biotech hits 100% response at top dose - Stock Titan
Single-dose lymphoma CAR-T from Legend Biotech hits 100% response at top dose Stock Titan
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma - Nature
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma Nature
Nivolumab Outperforms Brentuximab Vedotin in PFS in Classic Hodgkin Lymphoma - Targeted Oncology
Nivolumab Outperforms Brentuximab Vedotin in PFS in Classic Hodgkin Lymphoma Targeted Oncology
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch
Syncytial Variant of Nodular Sclerosis Classical Hodgkin’s Lymphoma With Hemophagocytic Lymphohistiocytosis: A Rare and Under-Characterized Entity - Cureus
Syncytial Variant of Nodular Sclerosis Classical Hodgkin’s Lymphoma With Hemophagocytic Lymphohistiocytosis: A Rare and Under-Characterized Entity Cureus
Low-Dose Nivolumab Offers Novel Strategy for Hodgkin Lymphoma Treatment - Targeted Oncology
Low-Dose Nivolumab Offers Novel Strategy for Hodgkin Lymphoma Treatment Targeted Oncology
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 - Fortune Business Insights
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 Fortune Business Insights
FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma - CancerNetwork
FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma CancerNetwork
Novel combination therapy yields high response rates in early-stage classical Hodgkin lymphoma - UT MD Anderson
Novel combination therapy yields high response rates in early-stage classical Hodgkin lymphoma UT MD Anderson
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials - Nature
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials Nature
Palmetto Sports’ Ella Grogan updates Clemson DT Hevin Brown-Shuler’s Hodgkin Lymphoma diagnosis. - Action News 5
Palmetto Sports’ Ella Grogan updates Clemson DT Hevin Brown-Shuler’s Hodgkin Lymphoma diagnosis. Action News 5
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin - UT MD Anderson
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin UT MD Anderson
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma - The ASCO Post
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma The ASCO Post
Nivolumab Wins Multiple FDA Approvals for Classical Hodgkin Lymphoma - Pharmacy Times
Nivolumab Wins Multiple FDA Approvals for Classical Hodgkin Lymphoma Pharmacy Times
Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story - Roswell Park Comprehensive Cancer Center
Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story Roswell Park Comprehensive Cancer Center
Durable 3-Year Superiority of N-AVD in Advanced Hodgkin Lymphoma - Targeted Oncology
Durable 3-Year Superiority of N-AVD in Advanced Hodgkin Lymphoma Targeted Oncology
‘The Sister Act’: How family and faith helped a young woman beat Hodgkin’s lymphoma - University of California - Davis Health
‘The Sister Act’: How family and faith helped a young woman beat Hodgkin’s lymphoma University of California - Davis Health
Clemson DT to miss 2026 season while undergoing treatment for Hodgkin lymphoma - The Athletic - The New York Times
Clemson DT to miss 2026 season while undergoing treatment for Hodgkin lymphoma - The Athletic The New York Times